Bax与PHF20蛋白在喉鳞状细胞癌中的表达及临床意义

张春明; 高伟; 董蜀斌; 陈钢钢; 韩瑞; 温树信; 王斌全

doi:10.13201/j.issn.1001-1781.2015.19.009

Bax与PHF20蛋白在喉鳞状细胞癌中的表达及临床意义

- 1. 山西医科大学第一医院耳鼻咽喉头颈外科(太原, 030001);
- 2. 耳鼻咽喉头颈肿瘤山西省重点实验室;
- 3. 山西省肿瘤医院头颈外科
基金项目:
国家自然科学基金(No:81572670)

山西省卫生厅科研课题(No:201301073)

山西医科大学科技创新基金(No:01201315)

山西医科大学第一医院院基金项目(No:09196#)

详细信息

通讯作者: 王斌全,E-mail:wbq_xy@sxent.org

中图分类号: R739.65

收稿日期: 2015-06-07

The expression and clinical significance of Bax and PHF20 in laryngeal squamous cell carcinoma

- 1 Department of Otolaryngology Head & Neck Surgery, the First Hospital, Shanxi Medical University, Taiyuan, 030001, China;
- 2 Shanxi Key Laboratory of Otorhinolaryngology Head and Neck Cancer;
- 3 Department of Head & Neck Surgery, Tumor Hospital of Shanxi Province

More Information

Corresponding author: WANG Binquan, E-mail: wbq_xy@sxent.org

Received Date: 07 June 2015

摘要

摘要: 目的: 探讨Bax和PHF20蛋白在喉鳞状细胞癌(LSCC)中的表达情况及临床意义。方法: 应用免疫组织化学SP法检测LSCC组织及癌旁正常黏膜组织中Bax与PHF20的表达情况,分析Bax和PHF20的表达与LSCC患者的临床分型、病理类型、组织学分级及淋巴结转移等临床病理参数之间的关系。结果: ①与癌旁切缘正常喉黏膜组比较,LSCC组中Bax和PHF20的表达量均明显降低,差异均有统计学意义(P<0.01)。②在临床分型中,LSCC声门上型、声门型、声门下型3组中Bax和PHF20蛋白表达量及表达阳性率差异均无统计学意义(P>0.05)。在组织学分化分组及病理学分型中,Bax和PHF20蛋白表达量及阳性表达率在低分化的LSCC组织中与高、中分化的LSCC组织相比,均显著降低(分别为P<0.01与P<0.05)。在T分期分组中,Bax和PHF20蛋白表达量及阳性率在T₁+T₂组均显著高于T₃+T₄组(均P<0.01)。在有无淋巴结转移分组中,无淋巴结转移的LSCC组织中Bax和PHF20的表达量及阳性率均明显高于发生淋巴结转移者(均P<0.01)。结论: Bax和PHF20的缺失可能与LSCC的发生及进展有关。进一步研究Bax和PHF20对LSCC细胞生物学行为的影响以及可能的分子调控机制,为明确LSCC发生发展提供了新的思路。
- 喉肿瘤 /
- 癌 /
- 鳞状细胞 /
- Bax /
- PHF20
Abstract: Objective: To investigate the expression of Bax and PHF20 in laryngeal squamous cell carcinoma(LSCC)and to discuss their relevance and the roles in carcinogenesis and development in LSCC.Method: The expressions of Bax and PHF20 in the LSCC tissues and normal mucosa tissues adjacent to carcinoma were detected by SP immunohistochemistry assay. The relationship between the expressions of Bax and PHF20 and the clinicopathological characteristics including clinical stage, pathological type, histological grade and lymph node metastasis in LSCC were analyzed according to the clinical data.Result: ①The expressions of Bax and PHF20 were both significantly lower in the LSCC tissue than that in the normal laryngeal tissue (P<0.01). ② In clinical stage grouping, there were no statistical differences of the quantity and positive rate of Bax and PHF20 expressions among supraglottic, glottic and subglottic LSCC (P>0.05). In histological differentiation grouping, the quantity and positive rate of Bax and PHF20 expressions decreased significantly in poorly differentiated LSCC compared with the well and moderately differentiated LSCCs (P<0.01, P<0.05, respectively). In T stage grouping, the quantity and positive rate of Bax and PHF20 expressions were both significantly higher in T₁+T₂ compared with T₃+T₄ (both P<0.01). In addition, the quantity and positive rate of Bax and PHF20 expressions were both significantly higher in LSCC with lymph node metastasis compared to that without lymph node metastasis (both P<0.01).Conclusion: The lack of Bax and PHF20 might contribute to the carcinogenesis and development in LSCC. The positive expression of Bax and PHF20 maybe relative to T term degree,differentiation degree and lymphamatic metastasis of LSCC.
- laryngeal neoplasms /
- carcinoma /
- squamous cell /
- Bax /
- PHF20

HTML全文

参考文献(22)

[1]	OLTVAI Z N, MILLIMAN C L, KORSMEYER S J. Bcl-2 heterodimerizes in vivo with a conserved homolog, Bax, that accelerates programmed cell death[J]. Cell, 1993,74:609-619.
[2]	KARABAY A Z, AKTAN F, SUNGUROGLU A, et al. Methylsulfonylmethane modulates apoptosis of LPS/IFN-gamma-activated RAW 264.7 macrophage-like cells by targeting p53, Bax, Bcl-2, cytochrome c and PARP proteins[J]. Immunopharmacol Immunotoxicol, 2014, 36:379-389.
[3]	HEISEL S M, KETTER R, KELLER A, et al. Increased seroreactivity to glioma-expressed antigen 2 in brain tumor patients under radiation[J]. PLoS One, 2008,3:e2164.
[4]	YIN Y, STEPHEN C W, LUCIANI M G, et al. p53 Stability and activity is regulated by Mdm2-mediated induction of alternative p53 translation products[J]. Nat Cell Biol, 2002,4:462-467.
[5]	CUI G, PARK S, BADEAUX A I, et al. PHF20 is an effector protein of p53 double lysine methylation that stabilizes and activates p53[J]. Nat Struct Mol Biol, 2012,19:916-924.
[6]	ZHOU J, ZHANG F, HOU X, et al. Downregulation of LRPPRC induces apoptosis in prostate cancer cells through the mitochondria-mediated pathway[J]. Cancer Biother Radiopharm, 2014, 29:345-350.
[7]	SAIGUSA S, INOUE Y, TANAKA K, et al. Lack of M30 expression correlates with factors reflecting tumor progression in rectal cancer with preoperative chemoradiotherapy[J]. Mol Clin Oncol, 2014,2:99-104.
[8]	ZHANG X, LU H, WANG Y, et al. Taurine induces the apoptosis of breast cancer cells by regulating apoptosis-related proteins of mitochondria[J]. Int J Mol Med, 2015,35:218-226.
[9]	GU C H, TIAN F Y, PU J R, et al. Over-expression of testis-specific expressed gene 1 attenuates the proliferation and induces apoptosis of GC-1spg cells[J]. J Huazhong Univ Sci Technolog Med Sci, 2014,34:535-541.
[10]	WANG H, ZHU L, GAO J, et al. Promotive role of recombinant HE4 protein in proliferation and carboplatin resistance in ovarian cancer cells[J]. Oncol Rep, 2015,33:403-412.
[11]	曹洪涛.胃癌组织中HIF-1α、Bax和Bcl-2蛋白的表达及其与肿瘤浸润转移的相关性[J].临床和实验医学杂志, 2014,13(8):631-633.
[12]	卫旭东,何健,高江霞,等.人喉癌Hep-2细胞系CD133⁺肿瘤干细胞自我更新机制研究[J].临床耳鼻咽喉头颈外科杂志, 2014,28(21):1636-1641.
[13]	FISCHER U, STRUSS A K, HEMMER D, et al. Glioma-expressed antigen 2(GLEA2):a novel protein that can elicit immune responses in glioblastoma patients and some controls[J]. Clin Exp Immunol, 2001,126:206-213.
[14]	PALLASCH C P, STRUSS A K, MUNNIA A, et al. Autoantibodies against GLEA2 and PHF3 in glioblastoma:tumor-associated autoantibodies correlated with prolonged survival[J]. Int J Cancer, 2005,117:456-459.
[15]	TANIWAKI M, DAIGO Y, ISHIKAWA N, et al. Gene expression profiles of small-cell lung cancers:molecular signatures of lung cancer[J]. Int J Oncol, 2006,29:567-575.
[16]	ADAMS-CIOABA M A, LI Z, TEMPEL W, et al. Crystal structures of the Tudor domains of human PHF20 reveal novel structural variations on the Royal Family of proteins[J]. FEBS Lett, 2012,586:859-865.
[17]	LASHO T L, PARDANANI A, TEFFERI A, et al. Altered expression of tumor suppressor PHF20 in myeloproliferative neoplasms[J]. Leukemia, 2014,28:1762-1764.
[18]	ZAATAR A M, LIM C R, BONG C W, et al. Whole blood transcriptome correlates with treatment response in nasopharyngeal carcinoma[J]. J Exp Clin Cancer Res, 2012,31:76-76.
[19]	RICHARD J M, SANCHO-GARNIER H, PESSEY J J, et al. Randomized trial of induction chemotherapy in larynx carcinoma[J]. Oral Oncol, 1998,34:224-228.
[20]	COHEN S M, GARRETT C G, DUPONT W D, et al. Voice-related quality of life in T₁ glottic cancer:irradiation versus endoscopic excision[J]. Ann Otol Rhinol Laryngol, 2006,115:581-586.
[21]	PARK S, KIM D, DAN H C, et al. Identification of Akt interaction protein PHF20/TZP that transcriptionally regulates p53[J]. J Biol Chem, 2012,287:11151-11163.
[22]	LI Y, PARK J, PIAO L, et al. PKB-mediated PHF20 phosphorylation on Ser291 is required for p53 function in DNA damage[J]. Cell Signal, 2013,25:74-84.